Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
moderate-intensity statin + ezetimibe
- Development stage
- Unknown
- Lead developer
- Yonsei University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A lipid-lowering treatment regimen consisting of a moderate-intensity statin (specifically pitavastatin 4 mg or atorvastatin 20 mg) combined with ezetimibe 10 mg. This combination is being investigated by Yonsei University in the ULTRA-CKD trial (NCT05936476) for the secondary prevention of cardiovascular events in patients with chronic kidney disease (CKD) and concomitant atherosclerotic cardiovascular disease (ASCVD). The regimen utilizes two distinct mechanisms: statins inhibit HMG-CoA reductase to reduce hepatic cholesterol synthesis, while ezetimibe targets the Niemann-Pick C1-Like 1 (NPC1L1) receptor to block intestinal cholesterol absorption. This dual-pathway approach is designed to achieve intensive LDL cholesterol lowering while potentially minimizing the muscle-related or metabolic adverse effects associated with high-intensity statin monotherapy.
- Other names
- moderate-intensity statin plus ezetimibe combination therapymoderate-intensity statin and ezetimibe combination therapyULTRA-CKD combination therapy
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on moderate-intensity statin + ezetimibe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on moderate-intensity statin + ezetimibe.